The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Natural history of infantile‐onset spinal muscular atrophy
Open accessAbstract
Objective: Infantile‐onset spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality, typically resulting in death preceding age 2. Clinical trials in this population require an understanding of disease progression and identification of meaningful biomarkers to hasten therapeutic development and predict outcomes. Methods: A longitudinal, multicenter, prospective natural history study enrolled 26 SMA infants and 27 control infants aged <6 months. Recruitment occurred at 14 centers over 21 months within the NINDS‐sponsored NeuroNEXT (National Network for Excellence in Neuroscience Clinical Trials) Network. Infant motor function scales (Test of Infant Motor Performance Screening Items [TIMPSI], The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders, and Alberta Infant Motor Score) and putative physiological and molecular biomarkers were assessed preceding age 6 months and at 6, 9, 12, 18, and 24 months with progression, correlations between motor function and biomarkers, and hazard ratios analyzed. Results: Motor function scores (MFS) and compound muscle action potential (CMAP) decreased rapidly in SMA infants, whereas MFS in all healthy infants rapidly increased. Correlations were identified between TIMPSI and CMAP in SMA infants. TIMPSI at first study visit was associated with risk of combined endpoint of death or permanent invasive ventilation in SMA infants. Post‐hoc analysis of survival to combined endpoint in SMA infants with 2 copies of SMN2 indicated a median age of 8 months at death (95% confidence interval, 6, 17). Interpretation: These data of SMA and control outcome measures delineates meaningful change in clinical trials in infantile‐onset SMA. The power and utility of NeuroNEXT to provide “real‐world,” prospective natural history data sets to accelerate public and private drug development programs for rare disease is demonstrated. Ann Neurol 2017;82:883–891
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Correlation between severity and SMN protein level in spinal muscular atrophy
Lefebvre, S., Burlet, P., Liu, Q., Bertrandy, S., Clermont, O., Munnich, A., Dreyfuss, G., & Melki, J. (1997) · Nature Genetics · doi:10.1038/ng0797-265 · Cited by 1,100
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,019
Self-citationFeldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961
Self-citationMonani, U. R. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1177 · Cited by 954
Monani, U. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.3.333 · Cited by 729
The survival motor neuron protein in spinal muscular atrophy
Coovert, D. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.8.1205 · Cited by 714
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy
Chiriboga, C. A., Swoboda, K. J., Darras, B. T., Iannaccone, S. T., Montes, J., De Vivo, D. C., Norris, D. A., Bennett, C. F., & Bishop, K. M. (2016) · Neurology · doi:10.1212/wnl.0000000000002445 · Cited by 612
Self-citationZerres, K. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540290108025 · Cited by 563
A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy
Kashima, T., & Manley, J. L. (2003) · Nature Genetics · doi:10.1038/ng1207 · Cited by 546
McAndrew, P. E., Parsons, D. W., Simard, L. R., Rochette, C., Ray, P. N., Mendell, J. R., Prior, T. W., & Burghes, A. H. M. (1997) · The American Journal of Human Genetics · doi:10.1086/515465 · Cited by 543
Self-citationMotor Assessment of the Developing Infant
Hurran, C. (1995) · Physiotherapy · doi:10.1016/s0031-9406(05)67120-9 · Cited by 534
Observational study of spinal muscular atrophy type I and implications for clinical trials
Finkel, R. S., McDermott, M. P., Kaufmann, P., Darras, B. T., Chung, W. K., Sproule, D. M., Kang, P. B., Foley, A. R., Yang, M. L., Martens, W. B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000741 · Cited by 528
Self-citationNatural history of denervation in SMA: Relation to age, SMN2 copy number, and function
Swoboda, K. J., Prior, T. W., Scott, C. B., McNaught, T. P., Wride, M. C., Reyna, S. P., & Bromberg, M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20473 · Cited by 478
Self-citationChildhood spinal muscular atrophy: controversies and challenges
Mercuri, E., Bertini, E., & Iannaccone, S. T. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70061-3 · Cited by 423
Self-citationGlanzman, A. M., Mazzone, E., Main, M., Pelliccioni, M., Wood, J., Swoboda, K. J., Scott, C., Pane, M., Messina, S., Bertini, E., et al. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2009.11.014 · Cited by 391
Self-citationSpinal Muscular Atrophy: A Timely Review
Kolb, S. J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.74 · Cited by 333
Self-citationA Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene
Prior, T. W., Krainer, A. R., Hua, Y., Swoboda, K. J., Snyder, P. C., Bridgeman, S. J., Burghes, A. H. M., & Kissel, J. T. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.08.002 · Cited by 321
Self-citationThe changing natural history of spinal muscular atrophy type 1
Oskoui, M., Levy, G., Garland, C. J., Gray, J. M., O’Hagen, J., De Vivo, D. C., & Kaufmann, P. (2007) · Neurology · doi:10.1212/01.wnl.0000290830.40544.b9 · Cited by 321
Prospective cohort study of spinal muscular atrophy types 2 and 3
Kaufmann, P., McDermott, M. P., Darras, B. T., Finkel, R. S., Sproule, D. M., Kang, P. B., Oskoui, M., Constantinescu, A., Gooch, C. L., Foley, A. R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318271f7e4 · Cited by 283
Self-citationRegulation of SMN Protein Stability
Burnett, B. G., Muñoz, E., Tandon, A., Kwon, D. Y., Sumner, C. J., & Fischbeck, K. H. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01262-08 · Cited by 281
Newborn and carrier screening for spinal muscular atrophy
Prior, T. W., Snyder, P. J., Rink, B. D., Pearl, D. K., Pyatt, R. E., Mihal, D. C., Conlan, T., Schmalz, B., Montgomery, L., Ziegler, K., et al. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33474 · Cited by 268
Self-citationA large animal model of spinal muscular atrophy and correction of phenotype
Duqué, S. I., Arnold, W. D., Odermatt, P., Li, X., Porensky, P. N., Schmelzer, L., Meyer, K., Kolb, S. J., Schümperli, D., Kaspar, B. K., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24332 · Cited by 154
Self-citationPearn, J. H. (1973) · Journal of Medical Genetics · doi:10.1136/jmg.10.3.260 · Cited by 147
Developmental milestones in type I spinal muscular atrophy
Sanctis, R. D., Coratti, G., Pasternak, A. E., Montes, J., Pane, M., Mazzone, E. S., Young, S. D., Salazar, R. L., Quigley, J., Pera, M. C., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.10.002 · Cited by 143
Self-citationBaseline results of the Neuro NEXT spinal muscular atrophy infant biomarker study
Kolb, S. J., Coffey, C. S., Yankey, J. W., Krosschell, K. J., Arnold, W. D., Rutkove, S. B., Swoboda, K. J., Reyna, S. P., Sakonju, A., Darras, B. T., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.283 · Cited by 126
Self-citationAn analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy
Elsheikh, B., Prior, T. W., Zhang, X., Miller, R. G., Kolb, S. J., Moore, D., Bradley, W. G., Barohn, R. J., Bryan, W. W., Gelinas, D. F., et al. (2009) · Muscle & Nerve · doi:10.1002/mus.21350 · Cited by 98
Self-citationSpinal muscular atrophy: Development and implementation of potential treatments
Arnold, W. D., & Burghes, A. H. M. (2013) · Annals of Neurology · doi:10.1002/ana.23995 · Cited by 95
Self-citationThe neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy
Arnold, W. D., McGovern, V. L., Sanchez, B., Li, J., Corlett, K. M., Kolb, S. J., Rutkove, S. B., & Burghes, A. H. M. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.12.014 · Cited by 49
Self-citationInterrater Reliability of Early Intervention Providers Scoring the Alberta Infant Motor Scale
Blanchard, Y., Neilan, E., Busanich, J., Garavuso, L., & Klimas, D. (2004) · Pediatric Physical Therapy · doi:10.1097/01.pep.0000113272.34023.56 · Cited by 47
Zaworski, P. G., von Herrmann, K. M., Taylor, S. J., Sunshine, S., McCarthy, K., Risher, N., Newcomb, T. M., Weetall, M. L., Prior, T. W., Swoboda, K. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150640 · Cited by 44
Self-citationCentral Institutional Review Board Review for an Academic Trial Network
Kaufmann, P., & O'Rourke, P. P. (2015) · Academic medicine : journal of the Association of American Medical Colleges · doi:10.1097/acm.0000000000000562 · Cited by 31
Reliability and Validity of the TIMPSI for Infants With Spinal Muscular Atrophy Type I
Krosschell, K. J., Maczulski, J. A., Scott, C., King, W. M., Hartman, J. T., Case, L. E., Viazzo‐Trussell, D., Wood, J., Roman, C. A., Hecker, E., et al. (2013) · Pediatric Physical Therapy · doi:10.1097/pep.0b013e31828a205f · Cited by 21
Self-citationNeuroNEXT: accelerating drug development in neurology
Neurology, T. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70008-x · Cited by 18
SMN Blood Levels in a Porcine Model of Spinal Muscular Atrophy
Iyer, C. C., Wang, X., Renusch, S. R., Duqué, S. I., Wehr, A. M., Mo, X.-M., McGovern, V. L., Arnold, W. D., Burghes, A. H. M., & Kolb, S. J. (2017) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-170209 · Cited by 14
Self-citationMcCulloch, C. E., & Searle, S. R. (2000) · Wiley series in probability and statistics · doi:10.1002/0471722073.ch6 · Cited by 5
Cited by
De Vivo, D. C., Bertini, E., Swoboda, K. J., Hwu, W.-L., Crawford, T. O., Finkel, R. S., Kirschner, J., Kuntz, N. L., Parsons, J. A., Ryan, M. M., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.09.007 · Cited by 629
Self-citationDay, J. W., Finkel, R. S., Chiriboga, C. A., Connolly, A. M., Crawford, T. O., Darras, B. T., Iannaccone, S. T., Kuntz, N. L., Peña, L. D. M., Shieh, P. B., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00001-6 · Cited by 494
Self-citationRisdiplam in Type 1 Spinal Muscular Atrophy
Baranello, G., Darras, B. T., Day, J. W., Deconinck, N., Klein, A., Masson, R., Mercuri, E., Rose, K., El-Khairi, M., Gerber, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2009965 · Cited by 436
Self-citationStrauss, K. A., Farrar, M. A., Muntoni, F., Saito, K., Mendell, J. R., Servais, L., McMillan, H. J., Finkel, R. S., Swoboda, K. J., Kwon, J. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01866-4 · Cited by 316
Self-citationGene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Metadata
- Authors
- Kolb, S. J., Coffey, C. S., Yankey, J. W., Krosschell, K., Arnold, W. D., Rutkove, S. B., Swoboda, K. J., Reyna, S. P., Sakonju, A., Darras, B. T., Shell, R., Kuntz, N., Castro, D., Parsons, J., Connolly, A. M., Chiriboga, C. A., McDonald, C., Burnette, W. B., Werner, K., Thangarajh, M., Shieh, P. B., Finanger, E., Cudkowicz, M. E., McGovern, M. M., McNeil, D. E., Finkel, R., Iannaccone, S. T., Kaye, E., Kingsley, A., Renusch, S. R., McGovern, V. L., Wang, X., Zaworski, P. G., Prior, T. W., Burghes, A. H. M., Bartlett, A., Kissel, J. T., & the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2017-12
- Volume
- 82
- Issue
- 6
- Pages
- 883-891
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2768938988
- Cited by
- 419
- References
- 38
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.